Bruno Pietro Imbimbo on Aducanumab Decision Delayed for Three Months
COMMENT We do not know which information FDA requested of Biogen. I do not believe the new data from the ongoing open-label extension trial on aducanumab represent significant information because of the uncontrolled nature of the study. Rather, I can speculate ...